







Regd. Office : A-1007,Sankalp Iconic Tower, Opp, Vikram Nagar,Iscon Temple Cross Road, S.G.Highway, Ahmedabad 380054,Gujarat,India

GST NO: 24AAACN6841KIZD

CIN: L24299GJ1992PLC01821

07th November, 2023

To,
The General Manager Corporation
Relationship Department BSE Limited
P.J Towers, Dalal Street
Mumbai - 400001
Script Code: 543207

To,
The Secretary
The Calcutta Stock Exchange Ltd.
7, Lyons Range
Kolkata – 700 001
Scrip Code: 24151

Dear Sir/Madam,

Sub: Outcome of the meeting of the Board of Directors held on Tuesday, November 07, 2023.

Ref: Regulation 30 & 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirement) Regulation, 2015.

With reference to above subject and in compliance with Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the outcome of the Meeting of the Board of Director held on today i.e., Tuesday, November 07, 2023 at 12:00 p.m. and concluded on 01:00 p.m. *inter alia* considered and approved the following:

- 1) Un-Audited Financial Results (UFR) for the second quarter and half year ended September 30, 2023, along with the Statutory Auditors' Limited Review Report.
- 2) Reviewed the disclosure of related party transactions for the first half year ended on September 30, 2023.
- 3) Reviewed the other businesses of the company.

Please take the same on record.

Thanking You

Yours faithfully,

^ 's'

For Natural Biocon (India) Limited

Arunkumar Prajapati Managing Director

DIN: 08281232

Encl. As Above

NATURAL BIOCON (INDIA) LIMITED CIN: L24299GJ1992PLC018210

Financial Results by Company

PART I (Rs. in Lakhs							
Statement of Standalone Unaudited Results for the Quarter and half year Ended 30/09/2023							
	Particulars	Quarter Ended 3 months ended Preceding 3 Corresponding		Corresponding	Haf Year Ended Year to date Year to date		Year Ended
			months ended	3 months ended in the previous year	figures for current period ended	figures for the previous year ended	
		(30/09/2023)	(30/06/2023)	(30/09/2022)	(30/09/2023)	(30/09/2022)	(31/03/2023)
_	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from Operation	324.08	27.12	35.34	351.20	44.34	125.43
	Other income	0.00	0.00	0.00	0.00	0.00	0.00
_	Total Revenue (I + II)	324.08	27.12	35.34	351.20	44.34	125.43
	Expenses	0.00	0.00	0.00	0.00	0.00	0.00
	(a) Cost of materials consumed	0.00	0.00	0.00	0.00 298.69	0.00 31.99	0.00
	(b) Purchase of stock-in-trade	298.69 7.71	0.00 14.96	30.00	298.69	0.00	173.99
	© Changes in inventories of finished goods, work-in-progress and stock-in-trade	/./1	14.96	0.00	22.07	0.00	(86.10)
_	(d) Employee benefits expense	0.00	3.20	0.34	3.20	3.55	4.53
	(e) Finance Cost	0.00	0.00	0.06	0.00	0.10	0.12
	(f) Depreciation and amortisation expense	0.00	0.00	0.00	0.00	0.00	0.00
	(g) Other expenses	3.76	3.61	3.02	7.37	4.69	8.19
	Total expenses	310.16	21.77	33.42	331.93	40.33	100.73
3	Profit / (Loss)before exceptional and extraordinary items and tax (III - IV)	13.92	5.35	1.92	19.27	4.01	24.70
4	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
	Profit / (Loss) before extraordinary items and tax (V - VI)	13.92	5.35	1.92	19.27	4.01	24.70
6	Tax expense - Provision for taxation						
	Current Tax - Provision for taxation	0.00	0.00	0.00	0.00	0.00	6.79
	Deferred Tax						
7	Net Profit / (Loss) for the period	13.92	5.35	1.92	19.27	4.01	17.91
8	Other Comprehensive Income/(Loss) (net of tax)	0.00	0.00	0.00	0.00	0.00	0.00
9	Total Comprehensive Income/(Loss) for the period	13.92	5.35	1.92	19.27	4.01	17.91
10	Paid up Equity Share Capital (Face value of Rs. 10/- each)	1137.28	1137.28	1137.28	1137.28	1137.28	1137.28
11	Earnings per equity share:						
	(1) Basic	0.01	0.00	0.00	0.02	0.04	0.02
	(2) Diluted	0.01	0.00	0.00	0.02	0.04	0.02
	11. /	1		1			

Notes:

- 1. The above unaudited financial results were reveiwed by the audit committee and approved by the board of directors at its meeting held on November 07, 2023.
- 2. These financial results have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 read with the relavent rules issued threreunder and other accounting principles generally accepted in India.
- 3. Disclosure of segment wise information is not applicable as the Company has only one business segment.
- ${\bf 4.\ Previous\ quarter's\ figures\ have\ been\ re-grouped\ /\ re-arranged\ wherever\ necessary.}$

By Order of the Board of Directors For Natural Biocon (India) Limited

Date:07/11/2023 Place: Ahmedabad

Arunkumar Prajapati Managing Director DIN: 08281232

NATURAL BIOCON (INDIA) LIMITED CIN: L24299GJ1992PLC018210

Stamenet Of Ass	Stamenet Of Assets and Liability						
	•	(Rs. In Lakhs)					
	Stan	dalone					
Particulars	As at 30th Sept						
1 at ticular s	2023	2023					
	Unaudited	Audited					
A) Assets							
Non Current Assets	0.60	0.60					
Property Plant and Equipement	0.69	0.69					
Capital Work In Progress	328.99	328.99					
Other Intengible Assets							
Intengible assets under Development							
Financial Assets							
i) Investment							
ii) Loan	824.59	806.95					
iii) Other Financial Assets	-						
Deferred Tax Assets (net)							
Other non current Assets	-	-					
Total Non Current Assets	1,154.27	1,136.63					
Current Assets							
Inventories	64.91	91.62					
Financial Assets							
i) Trade Receivable	172.80	62.82					
ii) Cash and Cash Equivalents	24.30	40.11					
iii) Bank Balance other than (ii)above	ı	-					
iv) Loans and Advances	ı	20.57					
iv) Investment	ı	ı					
Other Current Assets	ı	ı					
Total Curent Assets	262.01	215.12					
Total Assets	1,416.28	1,351.75					
B) Equity and Liabilities							
Equity Share Capital	1,137.28	1,137.28					
Other Equity	111.14	85.75					
Total Equity	1,248.42	1,223.03					
Non Current Liabilities	1,240.42	1,225.05					
Financial Liabilities							
i)Borrowings	_	_					
Defered Tax Liabilities	-	-					
Total Non Current Liabilities		-					
Current Liabilities	-	-					
Financial Liabilities							
i) Borrowings	18.53	15.43					
ii) Trade Payables	137.40	101.58					
iii) Other Financial Liabilities	137.40	101.30					
Provisions	9.31	9.95					
Other Current Liabilities	2.62	1.76					
Total Current Liabilities	167.86	128.72					
	1,416.28	1,351.75					
Total Equity and Liabilities	Ry Order of the Re	·					

By Order of the Board of Directors

For Natural Biocon (India) Limited

Date:07/11/2023 Place: Ahmedabad

> Arunkumar Prajapati Managing Director DIN: 08281232

NATURAL BIOCON (INDIA) LIMITED CIN: L24299GJ1992PLC018210

Cash Flow Statement		(Amount in Lacs)
Particulars	For the period ended on 30.09.2023	For the period ended on 31.03.2023
A. CASH FLOW FROM OPERATING ACTIVITIES	00.00.2020	0.1100.12020
Profit Before Tax	19.27	24.70
Adjustments for:		
Depreciation	0.00	0.00
Preliminery Exps. Written off		0.00
Finance Cost	0.00	-0.10
Dividend Written back/excess provision for taxation	0.00	0.00
Operating Profit before Working Capital Changes	19.27	24.60
Movements in Working Capital :		
Decrease / (Increase) in Inventories	26.71	-86.10
Decrease / (Increase) in Sundry Debtors	-109.98	-13.57
Decrease / (Increase) in Loans and Advances	20.57	0.00
Decrease / (Increase) in Current Assets	0.00	-3.17
(Decrease) / Increase in Trade Payables	35.82	99.33
(Decrease) / Increase in Short Term Provisions	-0.64	7.18
(Decrease) / Increase in Current Liabilities	0.00	-0.54
(Decrease) / Increase in Other Current Liabilities	0.86	0.00
Cash (used in) / generated from operations	-7.39	27.73
Direct Taxes Paid (net of refunds)		6.79
Net cash (used in) / generated from operating activities (A)	-7.39	20.94
B. CASH FLOW FROM INVESTING ACTIVITIES		
(Purchase) of Fixed Assets	0.00	
Purchase of Investment	0.00	
Sale / Disposal of Fixed Assets	0.00	0.00
Profit on sale of Investment / Assets	0.00	0.00
Net cash (used in) / generated from investing activities (B)	0.00	0.00
C. CASH FLOW FROM FINANCING ACTIVITIES		
(Repayment) / Proceeds From Long Term Borrowings	0.00	-1.86
(Repayment) / Proceeds From Short Term Borrowings	3.10	0.00
Repayment / (Proceeds) From Long Term Loans & Advances	-17.64	0.00
Adjustment from Reserves and surplus	6.12	
Proceeds from Issue of Shares	0.00	0.00
Interest Expense	0.00	0.10
Dividend Distribution Tax	0.00	0.00
Net cash (used in) / generated from financing activities (C)	-8.42	-1.76
D.NET INCREASE IN CASH AND CASH EQUIVALENTS (D)=(A+B+C)	-15.81	19.18
Cash and cash equivalents at the beginning of the year	40.11	20.93
Cash and cash equivalents at the end of the year	24.30	40.11
Components of cash and cash equivalents		
Cash and cheques on hand	24.30	40.02
With Scheduled Banks		
- in Current Account	0.00	0.09
- in Term Deposit Accounts		
	24.30	40.11

By Order of the Board of Directors For Natural Biocon (India) Limited

Date:07/11/2023 Place: Ahmedabad

> Arunkumar Prajapati Managing Director DIN: 08281232



Date: 07/11/2023

Place: Ahmedabad

Independent Auditor's Review Report on the Quarterly and Half Yearly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Limited Review Report to The Board of Directors of Natural Biocon (India) Limited

- 1. We have reviewed the accompanying statement of unaudited standalone financial results of Natural Biocon (India) Limited (the 'Company') for the quarter and half year ended September 30, 2023 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the Regulation') as amended, read with SEBI Circular No. CIRJCFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').
- 2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34. (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SIZE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Sanket Shah Chartered Accountants Mem. No. 150873 UDIN NO. 23150873BGSDSI3597

